Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Janux Therapeutics, Inc.JANX · Entity 4864 | Director · President and CEO | July 31, 2026 | August 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Janux Therapeutics, Inc.
Report date July 31, 2026 · Filed August 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 264,742 |
Reported balance
After 2026-07-31 transaction · row 1
1 source rowRow 1 · 2026-07-31 · Gift · Disposed 123,840 · Balance 264,742 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Aug 1, 2026 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GiftCommon Stock | 123,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001864158-26-000006 · form4-07312026_080701.xml · nonDerivative · entry 1 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,742 Read SEC document |
| July 08, 2026 Filed Jul 11, 2026 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001864158-26-000004 · form4-07102026_080702.xml · derivative · entry 2 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 697,550 Underlying: Common Stock · 7,000 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| July 08, 2026 Filed Jul 11, 2026 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 7,000 | $4.21 | $29,470.00 |
DisclosureSEC source: 0001864158-26-000004 · form4-07102026_080702.xml · nonDerivative · entry 1 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 388,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2026 Filed Jan 3, 2026 02:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock option (right to buy) · Derivative | 338,100 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0001864158-26-000002 · form4-01022026_090108.xml · derivative · entry 3 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,100 Underlying: Common Stock · 338,100 shares Expires 2036-01-01 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| January 02, 2026 Filed Jan 3, 2026 02:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 96,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001864158-26-000002 · form4-01022026_090108.xml · nonDerivative · entry 2 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 381,582 F2 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027. Read SEC document |
| January 02, 2026 Filed Jan 3, 2026 02:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 8,072 | $13.73 | $110,828.56 |
DisclosureSEC source: 0001864158-26-000002 · form4-01022026_090108.xml · nonDerivative · entry 1 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284,982 F1 · kind: The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document |
| January 07, 2025 Filed Jan 9, 2025 01:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 5,000 | $60.00 | $300,004.00 |
DisclosureSEC source: 0001415889-25-001165 · form4-01082025_080101.xml · nonDerivative · entry 1 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 293,054 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024. F2 · price: The weighted average sale price for the transaction reported was $60.0008 and the range of prices were between $60.00 and $60.02. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| January 02, 2025 Filed Jan 4, 2025 01:10 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock option (right to buy) · Derivative | 283,500 | $0.00 Strike: $53.24 | $0.00 |
DisclosureSEC source: 0001415889-25-000675 · form4-01032025_080107.xml · derivative · entry 2 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283,500 Underlying: Common Stock · 283,500 shares Expires 2035-01-01 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| January 02, 2025 Filed Jan 4, 2025 01:10 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 81,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000675 · form4-01032025_080107.xml · nonDerivative · entry 1 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 298,054 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026. Read SEC document |
| December 24, 2024 Filed Dec 28, 2024 01:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 25,000 | $56.19 | $1,404,805.00 |
DisclosureSEC source: 0001415889-24-030211 · form4-12272024_081201.xml · nonDerivative · entry 1 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 217,054 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024. F2 · price: The weighted average sale price for the transaction reported was $56.1922 and the range of prices were between $56.00 and $56.915. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 01:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 15,000 | $67.00 | $1,005,000.00 |
DisclosureSEC source: 0001415889-24-028203 · form4-12032024_081201.xml · nonDerivative · entry 1 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 242,054 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024. Read SEC document |
| November 25, 2024 Filed Nov 28, 2024 01:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 6,719 | $52.04 | $349,646.68 |
DisclosureSEC source: 0001415889-24-027905 · form4-11272024_081102.xml · nonDerivative · entry 2 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 257,054 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024. F3 · price: The weighted average sale price for the transaction reported was $52.0385 and the range of prices were between $51.89 and $52.385. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 25, 2024 Filed Nov 28, 2024 01:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 18,281 | $51.43 | $940,232.05 |
DisclosureSEC source: 0001415889-24-027905 · form4-11272024_081102.xml · nonDerivative · entry 1 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 263,773 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024. F2 · price: The weighted average sale price for the transaction reported was $51.4322 and the range of prices were between $50.89 and $51.885. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 28, 2024 Filed Oct 30, 2024 23:30 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 11,103 | $53.94 | $598,909.14 |
DisclosureSEC source: 0001415889-24-025792 · form4-10302024_071002.xml · nonDerivative · entry 2 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 282,054 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024. F3 · price: The weighted average sale price for the transaction reported was $53.9412 and the range of prices were between $53.58 and $54.445. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 28, 2024 Filed Oct 30, 2024 23:30 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 13,897 | $53.22 | $739,649.76 |
DisclosureSEC source: 0001415889-24-025792 · form4-10302024_071002.xml · nonDerivative · entry 1 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 293,157 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024. F2 · price: The weighted average sale price for the transaction reported was $53.2237 and the range of prices were between $52.5801 and $53.575. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 27, 2024 Filed Sep 27, 2024 23:30 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 795 | $47.84 | $38,031.53 |
DisclosureSEC source: 0001415889-24-024074 · form4-09272024_110948.xml · nonDerivative · entry 3 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,054 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024. F4 · price: The weighted average sale price for the transaction reported was $47.8384 and the range of prices were between $47.56 and $48.135. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 27, 2024 Filed Sep 27, 2024 23:30 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 5,248 | $46.86 | $245,895.04 |
DisclosureSEC source: 0001415889-24-024074 · form4-09272024_110948.xml · nonDerivative · entry 2 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,849 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024. F3 · price: The weighted average sale price for the transaction reported was $46.855 and the range of prices were between $46.565 and $47.54. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 27, 2024 Filed Sep 27, 2024 23:30 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 18,957 | $46.09 | $873,714.86 |
DisclosureSEC source: 0001415889-24-024074 · form4-09272024_110948.xml · nonDerivative · entry 1 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 313,097 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024. F2 · price: The weighted average sale price for the transaction reported was $46.0893 and the range of prices were between $45.55 and $46.54. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 356,500 | $0.00 Strike: $11.02 | $0.00 |
DisclosureSEC source: 0001209191-24-000431 · doc4.xml · derivative · entry 1 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356,500 Underlying: Common Stock · 356,500 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2025 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:30 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 310,000 | $0.00 Strike: $14.02 | $0.00 |
DisclosureSEC source: 0001209191-23-001867 · doc4.xml · derivative · entry 1 Campbell David Alan · CIK 0001864158 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,000 Underlying: Common Stock · 310,000 shares Expires 2033-01-02 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:21 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 354,250 | $0.00 Strike: $20.24 | $0.00 |
DisclosureSEC source: 0001209191-22-001813 · doc4.xml · derivative · entry 1 Campbell David Alan · CIK 0001864158 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,250 Underlying: Common Stock · 354,250 shares Expires 2032-01-02 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2023 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.